Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives

News

 9th April 2009
PolyTherics

PolyTherics to present recent developments in improving antibody fragments for therapeutic use at PEGS Protein Engineering Summit, Boston

London, United Kingdom – PolyTherics, the biopharmaceuticals company dedicated to precision engineering of protein half-life is pleased to announce its attendance at the 5th Annual PEGS conference in Boston, USA. Dr Ji-won Choi, Head of Biology will present data tomorrow showing that novel recombinant antibody fragments can be selectively modified by PEGylation without compromising their bioactivity. Dr Choi’s presentation will be featured in a session entitled “Recombinant Antibodies: From Concept to Clinic”, at 11.05am, EST.

Based in the London Bioscience Innovation Centre, PolyTherics has an established business in TheraPEG™, the application of polymer-based technology to proteins to develop a broad portfolio of biopharmaceuticals with selectively tailored half-life. PolyTherics’ discoveries have exciting potential for application in the field of next generation therapeutic antibodies.

:“We are delighted to be invited to present our discoveries at PEGS, given its recognition as the essential protein engineering summit for discovery, bioprocess and clinical developments in the field of Recombinant Antibodies and Therapeutic Proteins” comments Dr. Keith Powell, CEO of PolyTherics. “We plan to use this opportunity to promote our protein PEGylation expertise and seek new collaborative partnerships with antibody product-focused companies”.

The abstract of Dr. Choi’s talk will be available on request following the presentation.

For further information, please contact:

Dr. Keith Powell , CEO +44 (0) 207 691 4928 PolyTherics Ltd.

keith.powell@polytherics.co.uk

Mike Wort / Anna Dunphy +44 (0) 207 861 3838 De Facto Communications a.dunphy@defacto.com


 

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |